Abstract: The present disclosure relates to methods for selectively reducing CysL97 in a preparation of IL-17 antibodies or antigen binding fragments thereof (e.g., a preparation of secukinumab antibodies) that have been recombinantly produced by mammalian cells. Also provided are purified preparations of IL-17 antibodies or antigen binding fragments thereof produced by such methods, e.g, purified preparations of secukinumab, wherein the level of intact IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 90%, as measured by sodium dodecyl sulfate capillary electrophoresis (CE-SDS), and wherein the level of activity of IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 92%, as measured by cation exchange chromatograph (CEX).

Abstract: The present disclosure relates to methods for selectively reducing CysL97 in a preparation of IL-17 antibodies or antigen binding fragments thereof (e.g., a preparation of secukinumab antibodies) that have been recombinantly produced by mammalian cells. Also provided are purified preparations of IL-17 antibodies or antigen binding fragments thereof produced by such methods, e.g, purified preparations of secukinumab, wherein the level of intact IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 90%, as measured by sodium dodecyl sulfate capillary electrophoresis (CE-SDS), and wherein the level of activity of IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 92%, as measured by cation exchange chromatograph (CEX).

Abstract: The present invention relates to a choke with two coils and a core for interleaved applications in step-up or step-down circuits or power factor compensation circuits. The core comprises several core sections with several lateral legs and a middle leg, whereby the core is designed such, that a coupling factor k of the two coils is smaller than 3%-5%. Furthermore, the core is designed such, that the core section form two loops with the middle leg as a common section, whereby each of the two coils lies on different loops outside of the common section. The lateral legs have a cross section A1 and the middle leg for the common section has a cross section A2<2×A1.

Abstract: The present disclosure relates to methods for selectively reducing CysL97 in a preparation of IL-17 antibodies or antigen binding fragments thereof (e.g., a preparation of secukinumab antibodies) that have been recombinantly produced by mammalian cells. Also provided are purified preparations of IL-17 antibodies or antigen binding fragments thereof produced by such methods, e.g., purified preparations of secukinumab, wherein the level of intact IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 90%, as measured by sodium dodecyl sulfate capillary electrophoresis (CE-SDS), and wherein the level of activity of IL-17 antibodies or antigen binding fragments thereof (e.g., secukinumab) in the preparation is high, e.g., at least about 92%, as measured by cation exchange chromatograph (CEX).

Abstract: A rod-shaped magnetic core element, having a first end with a spherical or cylindrical recess or a spherical or cylindrical connecting protrusion, and a second end with a spherical or cylindrical recess or a spherical or cylindrical connecting protrusion so that a bent connection of at least two magnetic core elements is variably adjustable. Magnetic core elements comprising spherical or cylindrical magnetic core ends of this type allow a nearly gap-free construction with little magnetic leakage due to slightly larger end surfaces in comparison with ferrite rods having beveled plane end section surfaces. The enlarged end surface of the spherical surface advantageously allows a more stable connection of individual magnetic core elements without adhesive bonding. This allows the construction of flexible, multiple-member and inexpensive rod core coils and antennae.

Abstract: The present invention relates to a choke with two coils and a core for interleaved applications in step-up or step-down circuits or power factor compensation circuits. The core comprises several core sections with several lateral legs and a middle leg, whereby the core is designed such, that a coupling factor k of the two coils is smaller than 3%-5%. Furthermore, the core is designed such, that the core section form two loops with the middle leg as a common section, whereby each of the two coils lies on different loops outside of the common section. The lateral legs have a cross section A1 and the middle leg for the common section has a cross section A2<2×A1.

Abstract: A rod-shaped magnetic core element, having a first end with a spherical or cylindrical recess or a spherical or cylindrical connecting protrusion, and a second end with a spherical or cylindrical recess or a spherical or cylindrical connecting protrusion so that a bent connection of at least two magnetic core elements is variably adjustable. Magnetic core elements comprising spherical or cylindrical magnetic core ends of this type allow a nearly gap-free construction with little magnetic leakage due to slightly larger end surfaces in comparison with ferrite rods having beveled plane end section surfaces. The enlarged end surface of the spherical surface advantageously allows a more stable connection of individual magnetic core elements without adhesive bonding. This allows the construction of flexible, multiple-member and inexpensive rod core coils and antennae.

Abstract: This invention provides an isolated mutant atpE protein and departing from said mutant atpE protein the identification of an ATPase binding domain. This invention also provides related nucleic acids, vectors, host cells, pharmaceutical compositions and articles of manufacture. This invention further provides methods for determining whether a test compound interacts with an atpE protein, i.e. with the ATPase binding domain of the present invention, as well as pharmaceuticals compositions comprising said test compound, in particular as antimicrobials, more particular as antimycobacterial agent, even more particular for treating tuberculosis in a subject.

Abstract: This invention provides an isolated mutant atpE protein and departing from said mutant atpE protein the identification of an ATPase binding domain. This invention also provides related nucleic acids, vectors, host cells, pharmaceutical compositions and articles of manufacture. This invention further provides methods for determining whether a test compound interacts with an atpE protein, i.e. with the ATPase binding domain of the present invention, as well as pharmaceuticals compositions comprising said test compound, in particular as antimicrobials, more particular as antimycobacterial agent, even more particular for treating tuberculosis in a subject.

Abstract: This invention provides an isolated mutant atpE protein and departing from said mutant atpE protein the identification of an ATPase binding domain. This invention also provides related nucleic acids, vectors, host cells, pharmaceutical compositions and articles of manufacture. This invention further provides methods for determining whether a test compound interacts with an atpE protein, i.e. with the ATPase binding domain of the present invention, as well as pharmaceuticals compositions comprising said test compound, in particular as antimicrobials, more particular as antimycobacterial agent, even more particular for treating tuberculosis in a subject.

Abstract: This invention provides an isolated mutant atpE protein and departing from said mutant atpE protein the identification of an ATPase binding domain. This invention also provides related nucleic acids, vectors, host cells, pharmaceutical compositions and articles of manufacture. This invention further provides methods for determining whether a test compound interacts with an atpE protein, i.e. with the ATPase binding domain of the present invention, as well as pharmaceuticals compositions comprising said test compound, in particular as antimicrobials, more particular as antimycobacterial agent, even more particular for treating tuberculosis in a subject.

Abstract: A description is given of a gas-discharge lamp base (11) with a housing comprising an upper part (10) and a cover (40), a support (16) accommodated in the housing for receiving the components, with a transformer, with inductances connected in series with the lamp (1) and a capacitance connected in parallel with the lamp (1), the transformer comprising a bar transformer (23). This construction permits particularly efficient production, because the support can be constructed as a simple leadframe which permits automatic component fitting.

Abstract: An oscillating inductor has a symmetrical double-E core, which has two geometrically identical core windows, a cuboid center limb and two cuboid outer limbs. The double-E core is designed such that a longitudinal cross sectional area of the center limb is greater than 90 mm2, with a longitudinal cross section being regarded as a cross section which would separate the double-E core into two single E-cores, and the cross section being at right angles to the longitudinal cross section such that the double-E can be identified in the cross section, with the double-E core being located in a component volume of less than 26.5 mm×26.5 mm×15 mm (width×depth×height).

Abstract: An oscillating inductor has a symmetrical double-E core, which has two geometrically identical core windows, a cuboid center limb and two cuboid outer limbs. The double-E core is designed such that a longitudinal cross sectional area of the center limb is greater than 90 mm2, with a longitudinal cross section being regarded as a cross section which would separate the double-E core into two single E-cores, and the cross section being at right angles to the longitudinal cross section such that the double-E can be identified in the cross section, with the double-E core being located in a component volume of less than 26.5 mm×26.5 mm×15 mm (width×depth×height).

Abstract: A gas discharge lamp base (1) with a starting device has a carrier part (16) for electronic components (23 through 30) of the starting device. The carrier part (16) has a top side and a bottom side. Only high voltage-carrying components (23 through 26) of the starting device are arranged on the one side of the carrier part (16), and only low voltage-carrying components (27 through 30) of the starting device are arranged on the other side (low voltage side) of the carrier part (16).

Abstract: A description is given of a gas-discharge lamp base (11) with a housing comprising an upper part (10) and a cover (40), a support (16) accommodated in the housing for receiving the components, with a transformer, with inductances connected in series with the lamp (1) and a capacitance connected in parallel with the lamp (1), the transformer comprising a bar transformer (23). This construction permits particularly efficient production, because the support can be constructed as a simple leadframe which permits automatic component fitting.

Abstract: A method of casting has a mold assembled on a base plate. The finished mold is rotated by approximately 180° around a horizontal rotational axis. A casting container with an upwardly positioned aperture end, removed from the mold, is filled with melt for one casting operation. The casting container is sealingly coupled by the aperture end to the ingate end of the mold. The mold, together with its contacting casting container, is rotated by approximately 180° around a horizontal axis. Accordingly, the melt reaches the mold, and the casting container is removed from the coupled position away from the mold.

Abstract: The invention provides a two component system for in vitro cloning of a heterologous polynucleotide into adenoviral DNA. The first component is an insert donor comprising a heterologous polynucleotide encoding a heterologous polypeptide. The second component is a vector donor comprising an adenovirus genome and an expression cassette. The insert donor and vector donor are adapted for site specific recombination using recombination sites from phage lambda for insertion of the heterologous polynucleotide into the expression cassette capable of forming an adenoviral expression clone in vitro in the presence of a suitable recombination mediator protein or proteins. The invention also provides a method of making recombinant adenovirus and use of the first and second components in such a method.

Abstract: A method of casting has a mold assembled on a base plate. The finished mold is rotated by approximately 180° around a horizontal rotational axis. A casting container with an upwardly positioned aperture end, removed from the mold, is filled with melt for one casting operation. The casting container is sealingly coupled by the aperture end to the ingate end of the mold. The mold, together with its contacting casting container, is rotated by approximately 180° around a horizontal axis. Accordingly, the melt reaches the mold, and the casting container is removed from the coupled position away from the mold.